Free Trial

Adaptimmune Therapeutics (ADAP) SEC Filings & 10K Form

Adaptimmune Therapeutics logo
$0.28 +0.00 (+1.08%)
Closing price 04:00 PM Eastern
Extended Trading
$0.27 -0.01 (-3.76%)
As of 06:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Recent Adaptimmune Therapeutics SEC Filings

DateFilerForm TypeView
07/17/2025
3:30 PM
Adaptimmune Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/13/2025
6:35 AM
Adaptimmune Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/01/2025
3:15 PM
Adaptimmune Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/25/2025
7:02 AM
Adaptimmune Therapeutics (Filer)
Form DEF 14A
04/15/2025
7:00 AM
Adaptimmune Therapeutics (Filer)
Form PRE 14A
04/14/2025
3:10 PM
Adaptimmune Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/24/2025
3:40 PM
Adaptimmune Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/24/2025
3:44 PM
Adaptimmune Therapeutics (Filer)
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
03/20/2025
6:09 AM
Adaptimmune Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/20/2025
4:34 PM
Adaptimmune Therapeutics (Issuer)
Brewer Joanna Elizabeth (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/20/2025
4:35 PM
Adaptimmune Therapeutics (Issuer)
Bertrand William C JR (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/20/2025
4:30 PM
Adaptimmune Therapeutics (Issuer)
Rawcliffe Adrian (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/20/2025
4:31 PM
Adaptimmune Therapeutics (Issuer)
Norry Elliot (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/20/2025
4:32 PM
Adaptimmune Therapeutics (Issuer)
Piccina Cintia (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/20/2025
4:33 PM
Adaptimmune Therapeutics (Issuer)
Lunger John (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/14/2025
8:31 AM
Adaptimmune Therapeutics (Subject)
Two Seas Capital LP (Filed by)
Form SCHEDULE 13G
02/12/2025
9:25 AM
Adaptimmune Therapeutics (Subject)
BAILLIE GIFFORD & CO (Filed by)
Form SCHEDULE 13G/A
01/17/2025
8:15 PM
Adaptimmune Therapeutics (Issuer)
Rawcliffe Adrian (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/17/2025
8:16 PM
Adaptimmune Therapeutics (Issuer)
Bertrand William C JR (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/17/2025
8:17 PM
Adaptimmune Therapeutics (Issuer)
Lunger John (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/17/2025
8:17 PM
Adaptimmune Therapeutics (Issuer)
Norry Elliot (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/17/2025
2:07 PM
Adaptimmune Therapeutics (Subject)
Norry Elliot (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/17/2025
1:42 PM
Adaptimmune Therapeutics (Subject)
Rawcliffe Adrian (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/17/2025
1:50 PM
Adaptimmune Therapeutics (Subject)
Bertrand William C JR (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/17/2025
1:59 PM
Adaptimmune Therapeutics (Subject)
Lunger John (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/15/2025
3:15 PM
Adaptimmune Therapeutics (Issuer)
Bertrand William C JR (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/15/2025
3:16 PM
Adaptimmune Therapeutics (Issuer)
Lunger John (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/15/2025
3:17 PM
Adaptimmune Therapeutics (Issuer)
Norry Elliot (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/15/2025
3:18 PM
Adaptimmune Therapeutics (Issuer)
Piccina Cintia (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/15/2025
3:19 PM
Adaptimmune Therapeutics (Issuer)
Rawcliffe Adrian (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/15/2025
2:43 PM
Adaptimmune Therapeutics (Subject)
Lunger John (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/15/2025
2:50 PM
Adaptimmune Therapeutics (Subject)
Norry Elliot (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/15/2025
2:34 PM
Adaptimmune Therapeutics (Subject)
Rawcliffe Adrian (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/08/2025
9:30 AM
Adaptimmune Therapeutics (Subject)
Matrix Capital Management Company, LP (Filed by)
Form SCHEDULE 13G/A
12/19/2024
6:40 AM
Adaptimmune Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/05/2024
4:17 PM
Adaptimmune Therapeutics (Subject)
Matrix Capital Management Company, LP (Filed by)
Form SCHEDULE 13G/A
11/13/2024
8:04 AM
Adaptimmune Therapeutics (Subject)
Matrix Capital Management Company, LP (Filed by)
Form SC 13G/A
11/13/2024
8:10 AM
Adaptimmune Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/01/2024
4:00 PM
Adaptimmune Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/23/2024
3:15 PM
Adaptimmune Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/12/2024
6:23 AM
Adaptimmune Therapeutics (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
Critical AI announcement set to ignite AI 2.0 (Ad)

I just put together an urgent new presentation that you need to see right away. In short: I believe we are mere days away from a critical announcement from a key tech leader… One that will officially ignite “AI 2.0” – and potentially send a whole new class of stocks soaring.

Click to find out what Nvidia’s CEO might reveal… and how Sykes is preparing to ride the wave.
08/12/2024
6:05 AM
Adaptimmune Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/02/2024
6:00 AM
Adaptimmune Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
(Data available from 1/1/2016 forward)


Related Companies and Tools


This page (NASDAQ:ADAP) was last updated on 7/18/2025 by MarketBeat.com Staff
From Our Partners